Lithium toxicity following a change from semaglutide to tirzepatide for weight l...

연구 요약

Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.

The mental health clinician 학술지에 발표된 이 연구는 Burson JR, Leung JG 외 연구팀이 수행하였습니다.

이 연구는 'Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.'에 대한 과학적 분석을 제공합니다.

핵심 내용

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for weight management. Although generally well-tolerated, these agents may alter the pharmacokinetics of concurrently administered medications. CASE PRESENTATION: A 23-year-old male with schizoaffective disorder, bipolar type, developed lithium toxicity shortly after switching from semaglutide to tirzepatide. While taking semaglutide, the patient was started on lithium and titrated to 1800 mg nightly, corresponding to a level of 0.9 mEq/L. Four days after his first dose of tirzepatide, he reported early symptoms of potential lithium toxicity, which progressed significantly after the second dose. Symptoms corresponded to a 15-hour post-dose level of 1.7 mEq/L, despite no changes in renal function, hydration status, or other concurrent medications. Management with intravenous fluids was sufficient, and lithium dose reduction prevented future toxicity. DISCUSSION: Application of the Drug Interaction Probability Scale suggests a probable interaction between tirzepatide and lithium. The interaction might be mediated through delayed gastric emptying or other pharmacokinetic changes. Limited reports of GLP-1-modulating agents associated with lithium toxicity have been published and may be an underrecognized phenomenon. To date, no pharmacokinetic studies have been published evaluating this potential drug-drug interaction. Although many other medications seem to be at risk for decreased absorption, tirzepatide may enhance the absorption of lithium. CONCLUSION: Clinicians should be vigilant when initiating or switching GLP-1-modulating agents in patients receiving lithium. Pharmacokinetic studies are needed to clarify the mechanism of this interaction. Until more is known, increased monitoring of lithium levels is warranted, with initiation of a GLP-1-modulating agent, a dose change, or switching to another agent.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41646202)

📄 [전문 보기 (Markdown)](fulltext/41646202-lithium-toxicity-following-a-change-from-semaglutide-to-tirz.md)